systemic sclerosis with interstitial lung disease (ILD) in the course of the disease research hub

A multicentre clinical trial evaluating the safety and efficacy of the combination of nintedanib and tocilizumab compared to standard treatment in patients with systemic sclerosis and interstitial lung disease. Analysis with theranostic approach and assessment of cytokine activity, markers of inflammation and pulmonary fibrosis using computed tomography, positron emission tomography, and metabolome and transcriptome studies in selected patients. NINTOC-TU study

This study looks at new ways to treat a specific lung problem called interstitial lung disease (ILD) that can happen with a condition called systemic sclerosis. It compares a new combination of medicines with standard treatment to see if it can help improve breathing and reduce symptoms.